OTC:AAQL
Antiaging Quantum Living Inc.
A speculative OTC stock focused on emerging quantum applications for longevity research with significant cash reserves but substantial operating losses.
Key Metrics
Investment Thesis
Bull Case
Investors may buy AAQL as a high-risk, high-reward play on the convergence of quantum computing and the booming anti-aging industry before any commercial breakthroughs materialize. The company maintains over $0.3M in cash and equivalents, offering enough liquidity to survive while developing its unique IP portfolio.
Bear Case
The stock faces severe fundamental challenges including a negative profit margin of roughly -88% and a growing debt burden where liabilities exceed assets by more than one million dollars. With revenue only recently emerging from zero after two years of inactivity, the path to profitability remains unclear and highly uncertain.
About Antiaging Quantum Living Inc.
Antiaging Quantum Living Inc. specializes in developing advanced quantum technologies and anti-aging solutions, primarily serving the health tech and wellness sectors with proprietary research and development.
Analysis
Management Discussion
The company reported a significant cash outflow from operations of approximately $0.9M in 2025, driven by rising general and administrative costs of $1.1M and marketing expenses exceeding $0.15M. Despite generating $0.8M in revenue for the first time recently, the business continues to accumulate a substantial deficit, resulting in negative shareholders' equity.
Industry Overview
The anti-aging and longevity sector is experiencing exponential growth as consumers prioritize healthspan extension, yet it currently lacks standardized metrics or dominant players. Quantum technology integration offers a potential disruptive advantage but introduces significant regulatory and technical hurdles specific to this emerging industry.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $13.6K | $7.5K | $817.9K |
| Cost of Revenue | $0 | $771 | $389.4K |
| Gross Profit | $13.6K | $6.7K | $428.5K |
| Operating Expenses | $50.2K | $419.7K | $1.2M |
| Operating Income | $-36.6K | $-413.0K | $-790.0K |
| G&A | $50.2K | $348.5K | $1.1M |
| Marketing | — | $71.2K | $158.1K |
| D&A | — | $7.0K | $144.3K |
| Depreciation | $314 | $7.0K | $65.1K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $46 | $69.5K |
| Pre-Tax Income | $-36.6K | $-413.0K | $-720.4K |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-36.6K | $-413.0K | $-720.4K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-36.6K | $-413.0K | $-720.4K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-36.6K | $-413.0K | $-720.4K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $354 | $224.2K | $810.5K |
| Cash & Equivalents | $354 | $166.6K | $370.5K |
| Accounts Receivable | — | $2.0K | $85.8K |
| Other Current Assets | $0 | $55.7K | $354.2K |
| Long-Term Assets | $540 | $788.2K | $778.8K |
| PP&E (Net) | $540 | $215.8K | $120.8K |
| Intangibles | — | — | $13.6K |
| Operating Leases | — | $539.9K | $644.5K |
| Other LT Assets | $0 | $32.5K | $0 |
| Total Assets | $894 | $1.0M | $1.6M |
| Current Liabilities | $87.0K | $871.4K | $677.8K |
| Accounts Payable | $901 | — | — |
| Current Leases | — | $179.9K | $46.0K |
| Deferred Revenue | $2.8K | — | $8.5K |
| Other Current Liab | $83.3K | $691.6K | $623.3K |
| Long-Term Liabilities | $0 | $554.1K | $2.0M |
| LT Operating Leases | — | $134.9K | $366.7K |
| Other LT Liab | — | $419.2K | $1.7M |
| Total Liabilities | $87.0K | $1.4M | $2.7M |
| Shareholders' Equity | $-86.1K | $-413.2K | $-1.1M |
| Paid-In Capital | $160.2K | $243.5K | $243.5K |
| Retained Earnings | $-276.3K | $-689.3K | $-1.4M |
| AOCI | — | $2.6K | $6.2K |
| Total L&E | $894 | $1.0M | $1.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-36.6K | $-413.0K | $-720.4K |
| Non-Cash Adjustments | $314 | $-42.3K | $-242.6K |
| Working Capital Changes | $-1.9K | $-194.2K | $62.7K |
| Cash from Operations | $-38.2K | $-649.4K | $-900.3K |
| Cash from Investing | $0 | $-224.2K | $-63.3K |
| Cash from Financing | $24.3K | $1.0M | $1.2M |
| FX Effect | $0 | $-216 | $-415 |
| Net Change in Cash | $-13.9K | $166.4K | $204.4K |
| Beginning Cash | $14.3K | $354 | $166.6K |
| Ending Cash | $354 | $166.6K | $370.5K |
Frequently Asked Questions
How does Antiaging Quantum Living Inc. make money?
Proprietary quantum technology R&D, anti-aging product formulation, strategic partnerships in health tech, and potential licensing of intellectual property assets.
What are the main risks for AAQL?
Persistent net losses increasing the retained earnings deficit, high operating expenses relative to current revenue, limited liquidity compared to total liabilities, and dependence on successful commercialization of unproven quantum products.
What is AAQL's competitive advantage?
Access to cutting-edge quantum computing resources for molecular analysis, strong cash position providing runway for long-term R&D cycles, and early-mover advantage in the nascent longevity market.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.